Dapirolizumab pegol

Drug Profile

Dapirolizumab pegol

Alternative Names: Anti-CD40L Fab; Anti-CD40L Fab-PEG; CD40L - Fab; CDP-7657; Pegylated anti-CD40L antibody

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Biogen Idec; UCB
  • Developer Biogen; UCB
  • Class Antibodies; Fab fragments; Monoclonal antibodies; Polyethylene glycols
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Systemic lupus erythematosus
  • Preclinical Amyotrophic lateral sclerosis; Rheumatoid arthritis

Most Recent Events

  • 19 Sep 2016 Phase-II clinical trials in Systemic lupus erythematosus (Adjunctive treatment) in Germany, Hungary, Bulgaria, Spain (Parenteral) (EudraCT2015-004457-40)
  • 01 Jun 2016 Phase-II clinical trials in Systemic lupus erythematosus (Adjunctive treatment) in USA (Parenteral) (NCT02804763)
  • 18 Jun 2015 UCB and Biogen plan a phase II trial in Systemic lupus erythematosus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top